Literature DB >> 20213545

High density lipoprotein structure-function and role in reverse cholesterol transport.

Sissel Lund-Katz1, Michael C Phillips.   

Abstract

High density lipoprotein (HDL) possesses important anti-atherogenic properties and this review addresses the molecular mechanisms underlying these functions. The structures and cholesterol transport abilities of HDL particles are determined by the properties of their exchangeable apolipoprotein (apo) components. ApoA-I and apoE, which are the best characterized in structural terms, contain a series of amphipathic alpha-helical repeats. The helices located in the amino-terminal two-thirds of the molecule adopt a helix bundle structure while the carboxy-terminal segment forms a separately folded, relatively disorganized, domain. The latter domain initiates lipid binding and this interaction induces changes in conformation; the alpha-helix content increases and the amino-terminal helix bundle can open subsequently. These conformational changes alter the abilities of apoA-I and apoE to function as ligands for their receptors. The apoA-I and apoE molecules possess detergent-like properties and they can solubilize vesicular phospholipid to create discoidal HDL particles with hydrodynamic diameters of ~10 nm. In the case of apoA-I, such a particle is stabilized by two protein molecules arranged in an anti-parallel, double-belt, conformation around the edge of the disc. The abilities of apoA-I and apoE to solubilize phospholipid and stabilize HDL particles enable these proteins to be partners with ABCA1 in mediating efflux of cellular phospholipid and cholesterol, and the biogenesis of HDL particles. ApoA-I-containing nascent HDL particles play a critical role in cholesterol transport in the circulation whereas apoE-containing HDL particles mediate cholesterol transport in the brain. The mechanisms by which HDL particles are remodeled by lipases and lipid transfer proteins, and interact with SR-BI to deliver cholesterol to cells, are reviewed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20213545      PMCID: PMC3215094          DOI: 10.1007/978-90-481-8622-8_7

Source DB:  PubMed          Journal:  Subcell Biochem        ISSN: 0306-0225


  233 in total

Review 1.  The structure of apolipoprotein A-I in high density lipoproteins.

Authors:  W Sean Davidson; Thomas B Thompson
Journal:  J Biol Chem       Date:  2007-05-25       Impact factor: 5.157

2.  The roles of different pathways in the release of cholesterol from macrophages.

Authors:  Maria Pia Adorni; Francesca Zimetti; Jeffrey T Billheimer; Nan Wang; Daniel J Rader; Michael C Phillips; George H Rothblat
Journal:  J Lipid Res       Date:  2007-08-29       Impact factor: 5.922

3.  A monomeric, biologically active, full-length human apolipoprotein E.

Authors:  Yonghong Zhang; Sheeja Vasudevan; Radiya Sojitrawala; Wentao Zhao; Chunxian Cui; Chao Xu; Daping Fan; Yvonne Newhouse; Reeny Balestra; W Gray Jerome; Karl Weisgraber; Qianqian Li; Jianjun Wang
Journal:  Biochemistry       Date:  2007-08-23       Impact factor: 3.162

4.  Contributions of the carboxyl-terminal helical segment to the self-association and lipoprotein preferences of human apolipoprotein E3 and E4 isoforms.

Authors:  Takaaki Sakamoto; Masafumi Tanaka; Charulatha Vedhachalam; Margaret Nickel; David Nguyen; Padmaja Dhanasekaran; Michael C Phillips; Sissel Lund-Katz; Hiroyuki Saito
Journal:  Biochemistry       Date:  2008-01-18       Impact factor: 3.162

5.  Influence of tertiary structure domain properties on the functionality of apolipoprotein A-I.

Authors:  Masafumi Tanaka; Mao Koyama; Padmaja Dhanasekaran; David Nguyen; Margaret Nickel; Sissel Lund-Katz; Hiroyuki Saito; Michael C Phillips
Journal:  Biochemistry       Date:  2008-01-19       Impact factor: 3.162

6.  An analysis of the role of a retroendocytosis pathway in ABCA1-mediated cholesterol efflux from macrophages.

Authors:  Loren E Faulkner; Stacey E Panagotopulos; Jacob D Johnson; Laura A Woollett; David Y Hui; Scott R Witting; J Nicholas Maiorano; W Sean Davidson
Journal:  J Lipid Res       Date:  2008-03-22       Impact factor: 5.922

7.  Cholesterol is a determinant of the structures of discoidal high density lipoproteins formed by the solubilization of phospholipid membranes by apolipoprotein A-I.

Authors:  John B Massey; Henry J Pownall
Journal:  Biochim Biophys Acta       Date:  2008-03-21

8.  Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo.

Authors:  Xun Wang; Heidi L Collins; Mollie Ranalletta; Ilia V Fuki; Jeffrey T Billheimer; George H Rothblat; Alan R Tall; Daniel J Rader
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

9.  Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles.

Authors:  Charulatha Vedhachalam; Phu T Duong; Margaret Nickel; David Nguyen; Padmaja Dhanasekaran; Hiroyuki Saito; George H Rothblat; Sissel Lund-Katz; Michael C Phillips
Journal:  J Biol Chem       Date:  2007-06-29       Impact factor: 5.157

10.  Characterization and properties of pre beta-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-I.

Authors:  Phu T Duong; Ginny L Weibel; Sissel Lund-Katz; George H Rothblat; Michael C Phillips
Journal:  J Lipid Res       Date:  2008-02-05       Impact factor: 5.922

View more
  99 in total

1.  Central melanocortin signaling regulates cholesterol.

Authors:  Yi-Chun Loraine Tung; Giles S H Yeo
Journal:  Nat Neurosci       Date:  2010-07       Impact factor: 24.884

2.  Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.

Authors:  David O Osei-Hwedieh; Marcelo Amar; Dmitri Sviridov; Alan T Remaley
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

3.  HDL-apolipoprotein A-I exchange is independently associated with cholesterol efflux capacity.

Authors:  Mark S Borja; Kit F Ng; Angela Irwin; Jaekyoung Hong; Xing Wu; Daniel Isquith; Xue-Qiao Zhao; Bryan Prazen; Virginia Gildengorin; Michael N Oda; Tomáš Vaisar
Journal:  J Lipid Res       Date:  2015-08-07       Impact factor: 5.922

Review 4.  Is ABCA1 a lipid transfer protein?

Authors:  Michael C Phillips
Journal:  J Lipid Res       Date:  2018-01-05       Impact factor: 5.922

5.  Helix stabilization of amphipathic peptides by hydrocarbon stapling increases cholesterol efflux by the ABCA1 transporter.

Authors:  D O Sviridov; I Z Ikpot; J Stonik; S K Drake; M Amar; D O Osei-Hwedieh; G Piszczek; S Turner; A T Remaley
Journal:  Biochem Biophys Res Commun       Date:  2011-06-06       Impact factor: 3.575

6.  Stoichiometry of reconstituted high-density lipoproteins in the hydrated state determined by photon antibunching.

Authors:  Sonny Ly; Jitka Petrlova; Thomas Huser; Samantha Fore; Tingjuan Gao; John Voss; Ted A Laurence
Journal:  Biophys J       Date:  2011-08-17       Impact factor: 4.033

7.  Endothelial long non-coding RNAs regulated by oxidized LDL.

Authors:  Krishna K Singh; Pratiek N Matkar; Yi Pan; Adrian Quan; Vijay Gupta; Hwee Teoh; Mohammed Al-Omran; Subodh Verma
Journal:  Mol Cell Biochem       Date:  2017-03-18       Impact factor: 3.396

8.  ATP-binding cassette transporter A1: A promising therapy target for prostate cancer.

Authors:  Ting Xiong; Gang Xu; Xue-Long Huang; Kai-Qiang Lu; Wei-Quan Xie; Kai Yin; Jian Tu
Journal:  Mol Clin Oncol       Date:  2017-11-15

9.  Bone marrow-derived HL mitigates bone marrow-derived CETP-mediated decreases in HDL in mice globally deficient in HL and the LDLr.

Authors:  Neil J Hime; Audrey S Black; David J Bonnet; Linda K Curtiss
Journal:  J Lipid Res       Date:  2014-05-12       Impact factor: 5.922

10.  Effects of the Iowa and Milano mutations on apolipoprotein A-I structure and dynamics determined by hydrogen exchange and mass spectrometry.

Authors:  Palaniappan Sevugan Chetty; Maki Ohshiro; Hiroyuki Saito; Padmaja Dhanasekaran; Sissel Lund-Katz; Leland Mayne; Walter Englander; Michael C Phillips
Journal:  Biochemistry       Date:  2012-10-24       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.